- Home
- TTNP vs SNPX Comparison
TTNP vs SNPX Comparison
Compare TTNP & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- SNPX
- Stock Information
- Founded
- TTNP 1991
- SNPX 2012
- Country
- TTNP United States
- SNPX United States
- Employees
- TTNP N/A
- SNPX N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- TTNP Health Care
- SNPX Health Care
- Exchange
- TTNP Nasdaq
- SNPX Nasdaq
- Market Cap
- TTNP 3.4M
- SNPX 3.1M
- IPO Year
- TTNP 1996
- SNPX N/A
- Fundamental
- Price
- TTNP $4.67
- SNPX $2.16
- Analyst Decision
- TTNP
- SNPX Strong Buy
- Analyst Count
- TTNP 0
- SNPX 1
- Target Price
- TTNP N/A
- SNPX $14.00
- AVG Volume (30 Days)
- TTNP 42.9K
- SNPX 6.9K
- Earning Date
- TTNP 05-27-2025
- SNPX 05-15-2025
- Dividend Yield
- TTNP N/A
- SNPX N/A
- EPS Growth
- TTNP N/A
- SNPX N/A
- EPS
- TTNP N/A
- SNPX N/A
- Revenue
- TTNP N/A
- SNPX N/A
- Revenue This Year
- TTNP N/A
- SNPX N/A
- Revenue Next Year
- TTNP N/A
- SNPX N/A
- P/E Ratio
- TTNP N/A
- SNPX N/A
- Revenue Growth
- TTNP N/A
- SNPX N/A
- 52 Week Low
- TTNP $3.03
- SNPX $1.84
- 52 Week High
- TTNP $14.80
- SNPX $5.09
- Technical
- Relative Strength Index (RSI)
- TTNP 57.83
- SNPX 38.59
- Support Level
- TTNP $4.52
- SNPX $2.35
- Resistance Level
- TTNP $5.10
- SNPX $2.55
- Average True Range (ATR)
- TTNP 0.50
- SNPX 0.15
- MACD
- TTNP 0.07
- SNPX -0.01
- Stochastic Oscillator
- TTNP 49.77
- SNPX 0.00
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.